Combining ferroptosis inducers with gemcitabine to enhance treatment efficacy in pancreatic cancer
Authors:
Open Access
- 11 April 2026
- journal article
- research article
- Published by Springer Nature in Cancer & Metabolism
- Vol. 14 (1)
Abstract
Gemcitabine (GEM) is a standard chemotherapy for pancreatic cancer, but resistance limits its clinical benefit. The role of SRRM1, a splicing regulator, inKeywords
This publication has 30 references indexed in Scilit:
- 3D printed GelMA/HAMA based mechanical microenvironment boosted PDAC chemoresistance via NRF2-repressed ferroptosisColloids and Surfaces B: Biointerfaces, 2025
- DNAJC12 causes breast cancer chemotherapy resistance by repressing doxorubicin-induced ferroptosis and apoptosis via activation of AKTRedox Biology, 2024
- Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approachesEnvironmental Research, 2023
- The role of LOXL2 induced by glucose metabolism-activated NF-κB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDACJournal of Molecular Medicine, 2023
- Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4‐mediated Ferroptosis in Colorectal CancerAdvanced Science, 2023
- Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAsDrug Resistance Updates, 2023
- SRRM1 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by regulating the JAK/STAT signaling pathwayTissue and Cell, 2022
- Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosisCancer Letters, 2021
- Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancerEBioMedicine, 2020
- Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and DiseaseCell, 2017